This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by SUGINAMI, H. Articles by MATSUURA, S. Search for Related Content PubMed PubMed Citation Articles by SUGINAMI, H. Articles by MATSUURA, S.

Ovulation Induction with Bromocriptine in Normoprolactinemic Anovulatory Women^*

HIROSHI SUGINAMI, KATSUYUKI HAMADA, KOHJI YANO, GEORGE KURODA and SHUMPEI MATSUURA

Department of Obstetrics and Gynecology, Ehime University School of Medicine Shigenobu, Ehime 791-02, Japan

Afternoon-evening and nocturnal serum PRL levels and PRL responsiveness to metoclopramide (MCP) were determined in 34 women with normoprolactinemic anovulation (nPRL-Anov) and in the early follicular phase (EFP) in 6 normal women. Subsequently, the nPRL-Anov women were treated with 5 mg bromocriptine (Br) twice daily for 2 months, and its action on ovulation was determined. Those women who did not respond to Br received 50–150 mg clomiphene for 5 days.

The nPRL-Anov patients were classified into 3 groups in terms of the efficacy of Br treatment: group I, those who ovulated with Br (n = 13); group II, those who ovulated after receiving Br and clomiphene (n = 7); and group III, those who failed to ovulate after the above treatments (n = 10). Four patients dropped out of the study. Diurnal serum PRL levels were approximately 10 ng/ml in all patients, and no statistical difference was found among the groups. Peak nocturnal serum PRL levels (the highest PRL value during the 0000–0400 h period) were 38.0 ± 23.9 (±SD) ng/mlin group I patients, higher (P < 0.05) than in groups II and lit and normal (EFP) women (20.1 ± 9.1, 20.7 ± 7.7, and 16.3 ± 2.7 ng/ml for the group II and III patients and the EFP women, respectively). MCP induced rapid and marked elevation in serum PRL levels in all subjects. The maximum post-MCP PRL value in the group I patients was 224.2 ± 89.7 ng/ml, which was significantly higher (P < 0.002) than the maximum value in the remaining groups (120.5 ± 25.8, 121.3 ± 54.2, and 101.9 ± 28.1 ng/ml, respectively). Ten (76.9%) and 12 (92.3%) group I patients had nocturnal PRL levels above 25 ng/ml and maximumPRL values after MCP above 150 ng/ml, respectively.

We conclude that some nPRL-Anov patients have elevated nocturnal serum PRL levels or enhanced PRL responsiveness to MCP, indicative of nocturnal or latent hyperprolactinemia. Br effectively induced ovulation in these patients. A MCP provocation test can predict the outcome of Br treatment in such nPRL-Anov patients.

^* This work was supported in part by Sandoz, Japan.

To whom requests for reprints should be addressed.

Received September 13, 1985.